This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's strong product portfolio raises optimism about the stock.
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod
by Zacks Equity Research
QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.
QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 66.67% and 3.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Strength Seen in National Vision (EYE): Can Its 7.2% Jump Turn into More Strength?
by Zacks Equity Research
National Vision (EYE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.
Here's What Key Metrics Tell Us About QuidelOrtho (QDEL) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for QuidelOrtho (QDEL) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 2.33% and 1.96%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling QuidelOrtho (QDEL) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for QuidelOrtho (QDEL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
BioLife Solutions (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -19.05% and 2.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing
by Zacks Equity Research
QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
by Zacks Equity Research
QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.
QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.
QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall
by Zacks Equity Research
Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.
QuidelOrtho (QDEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for QuidelOrtho (QDEL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
QuidelOrtho (QDEL) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.08% and 6.97%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Insights Into QuidelOrtho (QDEL) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for QuidelOrtho (QDEL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
Medical Device Stocks' Earnings Due on Feb 13: ECL, DVA & QDEL
by Indrajit Bandyopadhyay
Medical Device companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how ECL, DVA and QDEL fare this time.
QuidelOrtho's (QDEL) Latest FDA Nod to Boost Diagnostic Testing
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's latest approval is likely to improve clinical care, provide cost savings and deliver sample-to-result molecular testing across all laboratory settings.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.